Inhibikase Therapeutics (NYSE:IKT – Free Report) had its target price cut by HC Wainwright from $27.00 to $23.00 in a report issued on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.37) […]